Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KN035 plus fluorouracil and oxaliplatin as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
CTR20181124Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Aug 2018
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Alphamab Oncology. Started Aug 2018; status: completed.
02
Drugs
envafolimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20181124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181124.